005690.KO Pharmicell

Healthcare Biotechnology Korea Stock Exchange
8,700 KRW
Close of Nov 5, 2026
8,140 21,150
Market cap
KRW 522B
P/E
-
P/B
3.78x
ROE
30.8%
Dividend yield
0.23%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 005690.KO undervalued?

Graham number

The Graham number of Pharmicell cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharmicell fundamental analysis

No fundamental analysis for Pharmicell yet.

Pharmicell stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cel…

Full company profile